AMMAR ALREFAI: Open Payments
NPI 1720044076 · MADISON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,263 in 108 payments from 19 companies in 2025. Trend: 2023 $3,084 · 2024 $2,906 · 2025 $2,263
Food & beverage: $2,263
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 16 | $404 |
| ABBVIE INC. | 23 | $325 |
| Neurocrine BioSciences, Inc. | 12 | $323 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $251 |
| Otsuka America Pharmaceutical, Inc. | 7 | $150 |
| Indivior Inc. | 4 | $129 |
| Corium, LLC | 5 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| Teva Pharmaceuticals USA, Inc. | 4 | $85 |
| Axsome Therapeutics, Inc. | 4 | $65 |
Products named: ARISTADA, VRAYLAR, INGREZZA, CAPLYTA, REXULTI, SUBLOCADE, Azstarys, TRINTELLIX.
Industry payments across AL — which companies pay providers there.
